The studies in this PS-OC will focus on evaluating a spectrum of EGFR- and RAF-targeted therapies in animal tumor models of glioblastoma (GBM) and melanoma brain metastases, and the Animal and Pharmacology Core will provide critical infrastructure for these studies. The Core will be led by Dr. Jann Sarkaria, who has extensive expertise in animal tumor models and by his long-time collaborator, Dr. William Elmquist, who is an expert in pharmacokinetic modeling of drug delivery into the brain. The main function of the Core will be to manage all aspects of the experiments that involve live animals and, in collaboration with the Administrative Core, to manage distribution of biospecimens and imaging data to the appropriate investigators. The Core will manage some experiments that are performed expressly for an individual project and others where the analysis of imaging and biospecimens will bridge both projects. The Core will have access to the extensive Mayo PDX xenograft collection in collaboration with the Mayo SPORE in Brain Cancer Animal Core. The key functions of the Core will include: 1. Develop and manage detailed experimental animal study plans 2. Pharmacokinetic and CNS distribution analyses of novel therapeutic agents 3. Perform therapeutic efficacy analyses 4. Conduct MR and bioluminescence imaging studies

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA210180-05
Application #
9994240
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2016-08-29
Project End
2021-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Massachusetts Institute of Technology
Department
Type
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Basu, Sankha S; Randall, Elizabeth C; Regan, Michael S et al. (2018) In Vitro Liquid Extraction Surface Analysis Mass Spectrometry (ivLESA-MS) for Direct Metabolic Analysis of Adherent Cells in Culture. Anal Chem 90:4987-4991
Randall, Elizabeth C; Emdal, Kristina B; Laramy, Janice K et al. (2018) Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma. Nat Commun 9:4904
Roos, Alison; Dhruv, Harshil D; Peng, Sen et al. (2018) EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival. Mol Cancer Res 16:1185-1195
Rothenberg, Daniel A; Taliaferro, J Matthew; Huber, Sabrina M et al. (2018) A Proteomics Approach to Profiling the Temporal Translational Response to Stress and Growth. iScience 9:367-381
Prahl, Louis S; Bangasser, Patrick F; Stopfer, Lauren E et al. (2018) Microtubule-Based Control of Motor-Clutch System Mechanics in Glioma Cell Migration. Cell Rep 25:2591-2604.e8
Kim, Minjee; Ma, Daniel J; Calligaris, David et al. (2018) Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier. Mol Cancer Ther 17:1893-1901
Laramy, Janice K; Kim, Minjee; Gupta, Shiv K et al. (2017) Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma. J Pharmacol Exp Ther 363:136-147
Emdal, Kristina B; Dittmann, Antje; Reddy, Raven J et al. (2017) Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance. Mol Cancer Ther 16:2572-2585
Gampa, Gautham; Vaidhyanathan, Shruthi; Sarkaria, Jann N et al. (2017) Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities? Pharmacol Res 123:10-25